Vendor Intelligence Report: Reta-Peptide

Executive summary

Across 225 Finnrick lab tests, Reta-Peptide records 171 pass / 53 fail, for an overall pass rate of 76%. The number hides a split catalog: GHK-Cu is the strongest line in the current record, Retatrutide is comparatively usable but not clean, and CJC-1295 and TB-500 are the clearest avoid-or-test-first signals. The full data also shows where stricter scoring changes the read on fill accuracy, not just purity.

Off the lab bench, the public identity is thinner than the storefront suggests. Reta-Peptide presents itself as a manufacturer with its own lab and production line, while an Echemi profile classifies the business as a Zhejiang, China trader established in 2024; searches did not surface a corroborating U.S. legal entity. The site itself routes orders through named sales staff and China shipping rather than a normal card checkout.

The investigation also follows a Retalux marketplace identity connected through Gavin’s @super_chem handle, a Shopify store history that began with Oils/Tablets categories, and a COA posture built around Janoshik while discouraging Finnrick testing. Reta-Peptide warns that Lazarus Labs Australia has misused its reports, but the captured materials do not show an authorized-channel list or public lot-verification system tying a buyer’s vial to an authenticated COA.

That makes the vendor a product-specific, lot-specific decision rather than a simple safe/unsafe call. Retatrutide buyers need the full context: the cumulative line is much stronger than the weak peptides, yet the investigation record includes severe historical outliers and missing batch-claim traceability.

Inside the full report:

• Appendix A — Finnrick Laboratory Data, with per-product breakdowns for all 13 tested products and methodology-divergence charts for the most-tested lines
• Corporate and marketplace evidence comparing manufacturer claims with Echemi trader disclosures
• Retalux / @super_chem linkage analysis across Reta-Peptide contact pages and Peptaura records
• COA and brand-verification review covering Janoshik links, the Lazarus Labs warning, and missing lot controls
• Payment, shipping, complaint-handling, and absence-trail findings from registries, ImportYeti, LinkedIn, and Trustpilot

Risk assessment

• High-failure product-line risk — high: CJC-1295 27.6%, TB-500 41.62%, BPC-157 47.49%, and Tesamorelin 49.18% are weak choices from this vendor in the current Finnrick record.
• Retatrutide critical-outlier and traceability risk — medium: Retatrutide rates 84.33% but investigation-record detail includes zero-active, extreme overfill, endotoxin detection, and absent batch-claim traceability.
• Counterparty-identity and manufacturer-claim risk — high: Site presents a manufacturer/own-lab operation; Echemi lists Trader in Zhejiang, domain dates to 2024, and no U.S. entity surfaced.
• Brand-confusion and COA-authentication risk — high: Reta-Peptide warns Lazarus Labs uses its reports, overlaps with Retalux, and lacks public authorized-channel or lot-verification controls in captured materials.
• Testing-accountability and complaint-handling risk — high: Captured page discourages Finnrick testing; Reddit user reported a ban after raising visible-debris contamination concerns.
• Payment and cross-border recourse risk — medium: Orders route via direct staff with T/T, BTC, USDT, or USDC and China-to-buyer shipping, limiting chargeback and domestic recourse.